274 related articles for article (PubMed ID: 33984191)
41. Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding.
Pignatelli P; Pastori D; Bartimoccia S; Menichelli D; Vicario T; Nocella C; Carnevale R; Violi F
Pharmacol Res; 2016 Nov; 113(Pt A):484-489. PubMed ID: 27693274
[TBL] [Abstract][Full Text] [Related]
42. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
Stöllberger C; Finsterer J
Herz; 2015 Apr; 40 Suppl 2():140-5. PubMed ID: 25616425
[TBL] [Abstract][Full Text] [Related]
43. Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement.
Seeger J; Gonska B; Rodewald C; Rottbauer W; Wöhrle J
JACC Cardiovasc Interv; 2017 Jan; 10(1):66-74. PubMed ID: 27916486
[TBL] [Abstract][Full Text] [Related]
44. Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation.
Esteve-Pastor MA; Rivera-Caravaca JM; Roldán V; Orenes-Piñero E; Romiti GF; Romanazzi I; Bai Y; Carmo J; Proietti M; Marín F; Lip GYH
Am J Cardiol; 2018 Sep; 122(5):785-792. PubMed ID: 30049460
[TBL] [Abstract][Full Text] [Related]
45. Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation.
Lutsey PL; Norby FL; Ensrud KE; MacLehose RF; Diem SJ; Chen LY; Alonso A
JAMA Intern Med; 2020 Feb; 180(2):245-253. PubMed ID: 31764956
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of characteristics and dosing regimens in patients with new or recurrent thrombosis on apixaban and rivaroxaban.
Dreucean D; Nguyen SN; Donahue KR; Salazar E; Ruegger MC
J Thromb Thrombolysis; 2021 Jul; 52(1):161-169. PubMed ID: 33099722
[TBL] [Abstract][Full Text] [Related]
47. Direct Oral Anticoagulants in Cardiac Amyloidosis-Associated Heart Failure and Atrial Fibrillation.
Mentias A; Alvarez P; Chaudhury P; Nakhla M; Moudgil R; Kanj M; Hanna M; Desai MY
Am J Cardiol; 2022 Feb; 164():141-143. PubMed ID: 34848050
[No Abstract] [Full Text] [Related]
48. Polypharmacy in the Elderly-When Good Drugs Lead to Bad Outcomes: A Teachable Moment.
Carroll C; Hassanin A
JAMA Intern Med; 2017 Jun; 177(6):871. PubMed ID: 28437544
[No Abstract] [Full Text] [Related]
49. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
Rutherford OW; Jonasson C; Ghanima W; Söderdahl F; Halvorsen S
Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):75-85. PubMed ID: 31942972
[TBL] [Abstract][Full Text] [Related]
50. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
[TBL] [Abstract][Full Text] [Related]
51. Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation.
Själander S; Sjögren V; Renlund H; Norrving B; Själander A
Thromb Res; 2018 Jul; 167():113-118. PubMed ID: 29803981
[TBL] [Abstract][Full Text] [Related]
52. Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation.
Hanna MS; Mohan P; Knabb R; Gupta E; Frost C; Lawrence JH
Ann N Y Acad Sci; 2014 Nov; 1329(1):93-106. PubMed ID: 25377080
[TBL] [Abstract][Full Text] [Related]
53. Rivaroxaban Versus Apixaban for Stroke Prevention in Atrial Fibrillation: An Instrumental Variable Analysis of a Nationwide Cohort.
Bonde AN; Martinussen T; Lee CJ; Lip GYH; Staerk L; Bang CN; Bhattacharya J; Gislason G; Torp-Pedersen C; Olesen JB; Hlatky MA
Circ Cardiovasc Qual Outcomes; 2020 Apr; 13(4):e006058. PubMed ID: 32283966
[TBL] [Abstract][Full Text] [Related]
54. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
55. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
Hijazi Z; Alexander JH; Li Z; Wojdyla DM; Mehran R; Granger CB; Parkhomenko A; Bahit MC; Windecker S; Aronson R; Berwanger O; Halvorsen S; de Waha-Thiele S; Sinnaeve P; Darius H; Storey RF; Lopes RD
Circulation; 2021 Mar; 143(12):1215-1223. PubMed ID: 33461308
[TBL] [Abstract][Full Text] [Related]
56. Anti-factor Xa activity, prothrombin time, and activated partial thromboplastin time in patients treated with factor Xa inhibitors.
Ono R; Nishimura K; Takahashi H; Hori Y; Fukushima K; Kobayashi Y
Naunyn Schmiedebergs Arch Pharmacol; 2023 Feb; 396(2):323-336. PubMed ID: 36326895
[TBL] [Abstract][Full Text] [Related]
57. Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials.
Nguyen E; White CM; Patel MR; Fields LE; Peacock WF; Crivera C; Coleman CI
Curr Med Res Opin; 2016 Jul; 32(7):1277-9. PubMed ID: 27009372
[TBL] [Abstract][Full Text] [Related]
58. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
Otsuka Y; Choules MP; Bonate PL; Komatsu K
CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
[TBL] [Abstract][Full Text] [Related]
59. Comparison of Low-Dose Direct Acting Anticoagulant and Warfarin in patients Aged ≥80 years With Atrial Fibrillation.
Chaudhry UA; Ezekowitz MD; Gracely EJ; George WT; Wolfe CM; Harper G; Harper GR
Am J Cardiol; 2021 Aug; 152():69-77. PubMed ID: 34162485
[TBL] [Abstract][Full Text] [Related]
60. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
Cini M; Legnani C; Padrini R; Cosmi B; Dellanoce C; De Rosa G; Marcucci R; Pengo V; Poli D; Testa S; Palareti G
Int J Lab Hematol; 2020 Apr; 42(2):214-222. PubMed ID: 32039550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
